202 related articles for article (PubMed ID: 29807222)
1. Cripto-1 promotes resistance to drug-induced apoptosis by activating the TAK-1/NF-κB/survivin signaling pathway.
Zhang Y; Mi X; Song Z; Li Y; YingShi ; Niu J
Biomed Pharmacother; 2018 Aug; 104():729-737. PubMed ID: 29807222
[TBL] [Abstract][Full Text] [Related]
2. Cripto-1 modulates macrophage cytokine secretion and phagocytic activity via NF-κB signaling.
Zhang DM; Bao YL; Yu CL; Wang YM; Song ZB
Immunol Res; 2016 Feb; 64(1):104-14. PubMed ID: 26476731
[TBL] [Abstract][Full Text] [Related]
3. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
4. Exogenous Cripto-1 Suppresses Self-Renewal of Cancer Stem Cell Model.
Alam MJ; Takahashi R; Afify SM; Oo AKK; Kumon K; Nawara HM; Khayrani AC; Du J; Zahra MH; Seno A; Salomon DS; Seno M
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30373174
[TBL] [Abstract][Full Text] [Related]
5. Cripto monoclonal antibodies.
Hu XF; Xing PX
Drug News Perspect; 2005 Jun; 18(5):293-303. PubMed ID: 16193101
[TBL] [Abstract][Full Text] [Related]
6. TAK-ing aim at chemoresistance: The emerging role of MAP3K7 as a target for cancer therapy.
Santoro R; Carbone C; Piro G; Chiao PJ; Melisi D
Drug Resist Updat; 2017 Nov; 33-35():36-42. PubMed ID: 29145973
[TBL] [Abstract][Full Text] [Related]
7. CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities.
Terry S; El-Sayed IY; Destouches D; Maillé P; Nicolaiew N; Ploussard G; Semprez F; Pimpie C; Beltran H; Londono-Vallejo A; Allory Y; de la Taille A; Salomon DS; Vacherot F
Oncotarget; 2015 May; 6(14):11994-2008. PubMed ID: 25596738
[TBL] [Abstract][Full Text] [Related]
8. Cripto-1: an embryonic gene that promotes tumorigenesis.
de Castro NP; Rangel MC; Nagaoka T; Salomon DS; Bianco C
Future Oncol; 2010 Jul; 6(7):1127-42. PubMed ID: 20624125
[TBL] [Abstract][Full Text] [Related]
9. Cripto as a target for cancer immunotherapy.
Hu XF; Xing PX
Expert Opin Ther Targets; 2005 Apr; 9(2):383-94. PubMed ID: 15934922
[TBL] [Abstract][Full Text] [Related]
10. URGCP/URG4 promotes apoptotic resistance in bladder cancer cells by activating NF-κB signaling.
Wu M; Chen J; Wang Y; Hu J; Liu C; Feng C; Zeng X
Oncotarget; 2015 Oct; 6(31):30887-901. PubMed ID: 26429874
[TBL] [Abstract][Full Text] [Related]
11. Blockade of Cripto binding to cell surface GRP78 inhibits oncogenic Cripto signaling via MAPK/PI3K and Smad2/3 pathways.
Kelber JA; Panopoulos AD; Shani G; Booker EC; Belmonte JC; Vale WW; Gray PC
Oncogene; 2009 Jun; 28(24):2324-36. PubMed ID: 19421146
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of Cripto-1 inhibits the proliferation, migration, invasion, and angiogenesis in prostate carcinoma cells.
Wu D; Shi Z; Xu H; Chen R; Xue S; Sun X
J Biosci; 2017 Sep; 42(3):405-416. PubMed ID: 29358554
[TBL] [Abstract][Full Text] [Related]
13. Administration of Cripto in GRP78 overexpressed human MSCs enhances stem cell viability and angiogenesis during human MSC transplantation therapy.
Kim S; Yoon YM; Han YS; Lee JH; Hur J; Lee SH
Cell Prolif; 2018 Oct; 51(5):e12463. PubMed ID: 29722092
[TBL] [Abstract][Full Text] [Related]
14. Biochemical and Cellular Analysis Reveals Ligand Binding Specificities, a Molecular Basis for Ligand Recognition, and Membrane Association-dependent Activities of Cripto-1 and Cryptic.
Aykul S; Parenti A; Chu KY; Reske J; Floer M; Ralston A; Martinez-Hackert E
J Biol Chem; 2017 Mar; 292(10):4138-4151. PubMed ID: 28126904
[TBL] [Abstract][Full Text] [Related]
15. NF-κB suppresses apoptosis and promotes bladder cancer cell proliferation by upregulating survivin expression in vitro and in vivo.
Cui X; Shen D; Kong C; Zhang Z; Zeng Y; Lin X; Liu X
Sci Rep; 2017 Jan; 7():40723. PubMed ID: 28139689
[TBL] [Abstract][Full Text] [Related]
16. Triptolide reverses the Taxol resistance of lung adenocarcinoma by inhibiting the NF-κB signaling pathway and the expression of NF-κB-regulated drug-resistant genes.
Jiang N; Dong XP; Zhang SL; You QY; Jiang XT; Zhao XG
Mol Med Rep; 2016 Jan; 13(1):153-9. PubMed ID: 26531258
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of nuclear translocation of nuclear factor-kappaB despite lack of functional IkappaBalpha protein overcomes multiple defects in apoptosis signaling in human B-cell malignancies.
Thomas RK; Sos ML; Zander T; Mani O; Popov A; Berenbrinker D; Smola-Hess S; Schultze JL; Wolf J
Clin Cancer Res; 2005 Nov; 11(22):8186-94. PubMed ID: 16299251
[TBL] [Abstract][Full Text] [Related]
18. Cripto binds transforming growth factor beta (TGF-beta) and inhibits TGF-beta signaling.
Gray PC; Shani G; Aung K; Kelber J; Vale W
Mol Cell Biol; 2006 Dec; 26(24):9268-78. PubMed ID: 17030617
[TBL] [Abstract][Full Text] [Related]
19. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
[TBL] [Abstract][Full Text] [Related]
20. Protective effect of caffeic acid on paclitaxel induced anti-proliferation and apoptosis of lung cancer cells involves NF-κB pathway.
Lin CL; Chen RF; Chen JY; Chu YC; Wang HM; Chou HL; Chang WC; Fong Y; Chang WT; Wu CY; Chiu CC
Int J Mol Sci; 2012; 13(5):6236-6245. PubMed ID: 22754361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
